Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Chronic Hepatitis C Clinical Trial

— 3DUTCH  

Official title:

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in The Netherlands (3DUTCH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02817594
• Other study ID #: P15-788
• Status: Completed
• Start date: January 20, 2016
• Est. completion date: March 7, 2018

Study information

• Verified date: January 2019
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions.

This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in the Netherlands in a clinical practice patient population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 7, 2018
• Est. primary completion date: March 7, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Treatment-naïve or -experienced adult male or female participants with confirmed CHC, genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label.

• If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy).

• Participants must voluntarily sign and date informed consent prior to inclusion into the study

Exclusion Criteria:

• Patients participating or intending to participate in a concurrent interventional therapeutic trial.

• Unable to complete the questionnaires due to cognitive impairment or lack of any kind of cognitive competence, as to be judged by the healthcare professional who is treating the patient.

• Unable to complete the questionnaires due to language incompetence.

• Unable to voluntarily sign and date the informed consent.

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Locations

Country	Name	City	State
Netherlands	Noordwest Ziekenhuisgroep /ID# 152604	Alkmaar
Netherlands	Duplicate_Onze Lieve Vrouwe Gasthuis /ID# 152600	Amsterdam
Netherlands	Albert Schweitzer Ziekenhuis /ID# 152597	Dordrecht	Zuid-Holland
Netherlands	Universitair Medisch Centrum Groningen /ID# 152596	Groningen
Netherlands	Leids Universitair Medisch Centrum /ID# 154637	Leiden
Netherlands	Radbound University Medical Ce /ID# 152598	Nijmegen
Netherlands	Erasmus Medisch Centrum /ID# 154635	Rotterdam
Netherlands	Maasstad Ziekenhuis /ID# 152592	Rotterdam
Netherlands	Universitair Medisch Centrum Utrecht /ID# 152595	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)	Sustained virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL 12 weeks after the last dose of study drug. Participants with missing HCV RNA were counted as virological failure.	12 weeks after the last dose of study drug (week 24 or 36 depending on the treatment regimen)
Secondary	Percentage of Participants Achieving Virological Response at End of Treatment	Virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL.	End of treatment (week 12 or 24 depending on the treatment regimen)
Secondary	Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Post-treatment	Sustained virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL 12 weeks after the last dose of study drug.; The Core Population with sufficient follow-up data regarding SVR12 included all core population participants who; had evaluable HCV RNA data = 70 days after the last actual dose of the ABBVIE REGIMEN; or a HCV RNA value = 50 IU/mL at the last measurement post-baseline; or had HCV RNA < 50 IU/mL at the last measurement post-baseline, but no HCV RNA measurement = 70 days after the last actual dose of the ABBVIE REGIMEN due to reasons related to safety (e.g. dropped out due to adverse event) or virologic failure.	12 weeks after the last dose of study drug (week 24 or 36 depending on the treatment regimen)
Secondary	Percentage of Participants With Relapse	Relapse was defined as participants with a virologic response (VR; HCV RNA < 50 IU/mL) at end of treatment (EOT) followed by HCV RNA = 50 IU/mL at any time after the end of treatment.	End of treatment (week 12 or 24 depending on the treatment regimen) and up to 24 weeks after the end of treatment.
Secondary	Percentage of Participants With Breakthrough	Breakthrough was defined as at least one documented HCV RNA < 50 IU/mL followed by HCV RNA = 50 IU/mL during treatment.	12 or 24 weeks (depending on the treatment regimen)
Secondary	Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment	SVR12 non-response was categorized according to the following: On-treatment virologic failure (breakthrough [at least one documented HCV RNA < 50 IU/mL followed by HCV RNA = 50 IU/mL during treatment] or failure to suppress [each measured on-treatment HCV RNA value = 50 IU/mL]); Relapse, defined as HCV RNA < 50 IU/mL at EOT followed by HCV RNA = 50 IU/mL post-treatment in patients who completed treatment (not more than 7 days shortened); Premature treatment discontinuation with no on-treatment virologic failure; Missing SVR12 data and/or none of the above criteria.	12 weeks after the last dose of study drug (week 24 or 36 depending on the treatment regimen)
Secondary	Percentage of the Direct Acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA	Adherence to study treatment was calculated as: Cumulative dose taken / (initial prescribed dose * planned duration)	From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen.
Secondary	Percentage of the Ribavirin Dose Taken in Relation to the Target Dose of Ribavirin	Adherence to study treatment was calculated as: Cumulative dose taken / (initial prescribed dose * planned duration)	From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen
Secondary	Percentage of Ribavirin (RBV) Treatment Days in Relation to the Target Number of Ribavirin Treatment Days		From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen.
Secondary	Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies		From first dose of study drug through 30 days after last dose (16 weeks).
Secondary	Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score	The EQ-5D-5L is a health state utility instrument that evaluates preference for health status. The 5 items in the EQ-5D-5L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 5 levels of severity (1: indicating no problem, 2: indicating slight problems, 3: indicating moderate problems, 4: indicating severe problems, 5: indicating extreme problems), and a separate visual analog scale (VAS).; Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score by applying country-specific weights.The range for EQ-5D-5L index score is 0 to 1 where '0' is defined as a health state equivalent to being dead and '1' is full health.The higher the score the better the health status.	Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment
Secondary	Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score	The EQ-5D-5L is a health state utility instrument that evaluates preference for health status with a separate visual analog scale (VAS).; The VAS assesses overall health on a scale from 0 (worst health imaginable) to 100 (best health imaginable).	Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment
Secondary	Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism	The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.; Absenteeism indicates the percentage of work time missed due to health problems.	Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment